Table 3 Response rate according to treatment arms

From: Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)

Objective response rate (ORR) (n = 120)

 

LV arm (n = 61)

V arm (n = 59)

 

CR or PR

12

10

 

SD/PD

49

49

ORR

 

19.67%

16.94%

   

P = 0.8812

FAS (n = 147)

 

LV arm (n = 75)

V arm (n = 72)

CBR

CR + PR + SD ≥ 24 weeks

25 (33.3%)

17 (23.6%)

 

CR + PR + SD < 24 weeks or PD

50 (66.7%)

55 (76.4%)

   

P = 0.192

  1. FAS full analysis set, CBR clinical benefit ratio, CR complete response, PR partial response, SD stable disease
Back to article page